The Day Amarin Investors Have Waited For

After yet another FDA delay regarding Vascepa's NCE status, Amarin (NASDAQ: AMRN  ) investors may have something to celebrate today: The company stayed true to its reported timeline and has launched its lipid-lowering drug. While this launch does signify progress at the company, it will go head to head with Lovaza, a drug marketed by pharma giant GlaxoSmithKline (NYSE: GSK  ) . In this video, our health care analyst Max Macaluso discusses whether this is news investors should welcome -- and what they should be wary of.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air,  the success of Vascepa is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with the Fool's premium research report on this biotech. Click here now to keep reading.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 27, 2013, at 8:05 PM, eyehelper wrote:

    Fish oil = fish oil , the science requires a re -esterified Triglyceride form for best absorption into the body. The real question is will docs prescribe it right and left instead of patients going to natural real fish oils or other over the counter effective and clean techniques (lowest mercury and PCB levels) of production. BIG PHARMA DOES NOT OWN THE SCIENCE ,, just the marketing.

  • Report this Comment On January 28, 2013, at 12:43 AM, SamFreedom wrote:

    "But, Dr., I would rather eat a couple pieces of salmon each week for starters."

    Doc: Ok, see how that works first.

Add your comment.

DocumentId: 2214164, ~/Articles/ArticleHandler.aspx, 7/23/2014 5:10:43 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement